Literature DB >> 21380926

The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line.

Yang-Yang Zhang1, Ke-Ming Xie1, Guo-Qing Yang2, Hui-Jun Mu3, Ying Yin3, Bin Zhang3, Ping Xie4.   

Abstract

Previous work from our laboratory demonstrated that glucosylceramide synthase (GCS) and multidrug resistance 1 gene (MDR1) are co-overexpressed in drug-resistant leukemia cells. We hypothesized that GCS and MDR1 may interact. In this study, we used RNA interference (RNAi) to silence the GCS or MDR1 gene in K562/AO2 drug-resistant cells. The sensitivity of cells to different treatments with doxorubicin was evaluated. We used Taqman probe fluorescence real-time quantitative PCR, and detected expression of GCS and MDR1 mRNAs in different interfering groups. Intracellular mean fluorescence intensity (MFI), which represents rhodamine123 (rh123) retention, was determined by flow cytometry (FCM). An MTT cytotoxicity assay showed that the 50% inhibition concentration (IC50) of doxorubicin of K562/AO2 cells (138.25 ± 3.75 µg/ml) was significantly higher than that of K562 drug-sensitive cells (2.125 ± 0.125 µg/ml), and that IC50 was evidently lower in K562/AO2 cells, whether it was transfected with a small interfering RNA (siRNA) targeting GCS (GCSsiRNA) or one targeting MDR1 (MDR1siRNA). Compared with untreated K562/AO2 cells, the inhibition rates of GCS mRNA in the cells transfected with GCSsiRNA for 9 and 36 h were 56.67 ± 9.29% (p < 0.05) and 74 ± 6.38% (p < 0.05), respectively. Interestingly, the expression of MDR1 mRNA was also inhibited to 51.7 ± 4.5% (p < 0.05) 36 h after transfection with GCSsiRNA, but there was no significant difference in MDR1 expression at 9 h post-transfection in cells treated with GCSsiRNA and a negative control. It is well known that rh123 retention in cells results from an efflux function of P-glycoprotein (P-gp). In K562 cells, rh123 retention was much higher than in K562/AO2 cells (p < 0.01). We also noted that rh123 retention in the K562/AO2 cells transfected with GCSsiRNA for 48 h was significantly higher than in the negative control group. In conclusion, we show in the present study that inhibition of the GCS gene affects the expression of MDR1 mRNA and P-gp function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21380926     DOI: 10.1007/s12185-011-0798-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

Review 1.  Physiology and pathophysiology of sphingolipid metabolism and signaling.

Authors:  A Huwiler; T Kolter; J Pfeilschifter; K Sandhoff
Journal:  Biochim Biophys Acta       Date:  2000-05-31

Review 2.  Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.

Authors:  B I Sikic; G A Fisher; B L Lum; J Halsey; L Beketic-Oreskovic; G Chen
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

3.  Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets.

Authors:  H Morjani; N Aouali; R Belhoussine; R J Veldman; T Levade; M Manfait
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 4.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

Review 5.  Clinical significance of P-glycoprotein in multidrug resistance malignancies.

Authors:  R J Arceci
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

6.  Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.

Authors:  Valérie Gouazé; Yong-Yu Liu; Carlton S Prickett; Jing Y Yu; Armando E Giuliano; Myles C Cabot
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

7.  Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis.

Authors:  María Fabiana De Rosa; Daniel Sillence; Cameron Ackerley; Clifford Lingwood
Journal:  J Biol Chem       Date:  2003-12-08       Impact factor: 5.157

8.  Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.

Authors:  Gareth Gerrard; Terry D Butters; Kanagasabai Ganeshaguru; Atul B Mehta
Journal:  Eur J Pharmacol       Date:  2009-03-12       Impact factor: 4.432

Review 9.  Multidrug resistance in hematological malignancy.

Authors:  Masao Hirose; Eiji Hosoi; Shuichi Hamano; Ali Jalili
Journal:  J Med Invest       Date:  2003-08

10.  Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells.

Authors:  Ping Xie; Yun-Fen Shen; Yuan-Ping Shi; Shu-Mei Ge; Zhong-Hua Gu; Jue Wang; Hui-Jun Mu; Bin Zhang; Wei-Zhen Qiao; Ke-Ming Xie
Journal:  Leuk Res       Date:  2007-08-20       Impact factor: 3.156

View more
  6 in total

Review 1.  Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.

Authors:  Yong-Yu Liu; Ronald A Hill; Yu-Teh Li
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

2.  Glucosylceramide synthase promotes Bcl-2 expression via the ERK signaling pathway in the K562/A02 leukemia drug-resistant cell line.

Authors:  Qian Wang; Jian Zou; Xiufen Zhang; Huijun Mu; Ying Yin; Ping Xie
Journal:  Int J Hematol       Date:  2014-10-04       Impact factor: 2.490

Review 3.  Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.

Authors:  Kazuyuki Kitatani; Makoto Taniguchi; Toshiro Okazaki
Journal:  Mol Cells       Date:  2015-05-22       Impact factor: 5.034

Review 4.  Translational Aspects of Sphingolipid Metabolism in Renal Disorders.

Authors:  Alaa Abou Daher; Tatiana El Jalkh; Assaad A Eid; Alessia Fornoni; Brian Marples; Youssef H Zeidan
Journal:  Int J Mol Sci       Date:  2017-11-25       Impact factor: 5.923

5.  Next generation deep sequencing identified a novel lncRNA n375709 associated with paclitaxel resistance in nasopharyngeal carcinoma.

Authors:  Shuling Ren; Guo Li; Chao Liu; Tao Cai; Zongwu Su; Ming Wei; Li She; Yongquan Tian; Yuanzheng Qiu; Xin Zhang; Yong Liu; Yunyun Wang
Journal:  Oncol Rep       Date:  2016-07-28       Impact factor: 3.906

6.  Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia.

Authors:  Chunfa Huang; Yifan Tu; Carl E Freter
Journal:  Oncotarget       Date:  2018-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.